A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2009-11-19
Target enrollment:
Participant gender:
Summary
This open-label, single-arm, multicenter trial is designed to evaluate the safety of
erlotinib in combination with standard of care chemotherapy (gemcitabine) in participants
with locally advanced, unresectable, or metastatic pancreatic cancer.